Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

We are pleased that the FDA has accepted our submission and look forward to working with regulatory authorities on what would be the first oral GLP-1 treatment for obesity." ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved ... In contrast, Pfizer announced it would stop developing danuglipron, an oral GLP-1 pill, after a ...

Findings showed a 13.6% reduction in body weight in the semaglutide ... and look forward to working with regulatory authorities on what would be the first oral [glucagon-like peptide-1] treatment ...